An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.
Talga Group has received a significant A$13.35 million grant from the Swedish Energy Agency to advance its sustainable battery anode manufacturing project, aiming for near-industrial scale validation by mid-2026.
